---
authors:
- Nodelman, Matthew
- Scott, A Miles
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/38905561/
file_path: 2024/06/rsvpref-abrysvo-and-nirsevimab-alip-beyfortus-for-the-preven.md
issue: '6'
keywords:
- Palivizumab
- Respiratory
- Humans
- Infant
- Antibodies, Monoclonal, Humanized
- Viral Vaccines
- Antiviral Agents
- Respiratory Syncytial Virus Vaccines
- Respiratory Syncytial Virus Infections
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Respiratory Syncytial Virus Infections
- Antiviral Agents
- Antibodies, Monoclonal, Humanized
- Infant
- Palivizumab
- Viral Vaccines
- Respiratory Syncytial Virus Vaccines
original_format: PubMed
pages: 578-579
patient_population: Adults
peer_reviewed: true
pmid: '38905561'
processed_date: '2025-07-30'
publication_date: '2024-06-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory
  Syncytial Virus Infection.
topics:
- Respiratory Disorders
- Family Medicine
- Pulmonology
volume: '109'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '38905561'
  title: RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory
    Syncytial Virus Infection.
  authors:
  - last_name: Nodelman
    fore_name: Matthew
    initials: M
    affiliation: Prisma Health/University of South Carolina School of Medicine-Columbia,
      Columbia, South Carolina.
  - last_name: Scott
    fore_name: A Miles
    initials: AM
    affiliation: Prisma Health/University of South Carolina School of Medicine-Columbia,
      Columbia, South Carolina.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '109'
    issue: '6'
  publication_info:
    year: '2024'
    month: '06'
    full_date: '2024-06-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Respiratory Syncytial Virus Infections
    major_topic: true
    qualifiers:
    - qualifier: prevention & control
      major_topic: false
  - descriptor: Antiviral Agents
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Antibodies, Monoclonal, Humanized
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Infant
    major_topic: false
  - descriptor: Palivizumab
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Viral Vaccines
    major_topic: false
  - descriptor: Respiratory Syncytial Virus Vaccines
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '38905561'
  title: RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory
    Syncytial Virus Infection.
  authors:
  - name: Nodelman M
    authtype: Author
    clusterid: ''
  - name: Scott AM
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Jun
- pmid: '39079810'
  title: Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of
    respiratory syncytial virus disease in Canadian infants.
  authors:
  - name: Gebretekle GB
    authtype: Author
    clusterid: ''
  - name: Yeung MW
    authtype: Author
    clusterid: ''
  - name: Ximenes R
    authtype: Author
    clusterid: ''
  - name: Cernat A
    authtype: Author
    clusterid: ''
  - name: Simmons AE
    authtype: Author
    clusterid: ''
  - name: Killikelly A
    authtype: Author
    clusterid: ''
  - name: Siu W
    authtype: Author
    clusterid: ''
  - name: Rafferty E
    authtype: Author
    clusterid: ''
  - name: Brousseau N
    authtype: Author
    clusterid: ''
  - name: Tunis M
    authtype: Author
    clusterid: ''
  - name: Tuite AR
    authtype: Author
    clusterid: ''
  source: Vaccine
  pubdate: 2024 Aug 30
- pmid: '34456918'
  title: 'Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric
    Vaccines and Implications for Nirsevimab Use: A White Paper.'
  authors:
  - name: Esposito S
    authtype: Author
    clusterid: ''
  - name: Abu-Raya B
    authtype: Author
    clusterid: ''
  - name: Bonanni P
    authtype: Author
    clusterid: ''
  - name: Cahn-Sellem F
    authtype: Author
    clusterid: ''
  - name: Flanagan KL
    authtype: Author
    clusterid: ''
  - name: Martinon Torres F
    authtype: Author
    clusterid: ''
  - name: Mejias A
    authtype: Author
    clusterid: ''
  - name: Nadel S
    authtype: Author
    clusterid: ''
  - name: Safadi MAP
    authtype: Author
    clusterid: ''
  - name: Simon A
    authtype: Author
    clusterid: ''
  source: Front Immunol
  pubdate: '2021'
- pmid: '38070539'
  title: Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated
    Lower Respiratory Tract Infections in Infants and Children up to 24 Months of
    Age.
  authors:
  - name: Cieslak CM
    authtype: Author
    clusterid: ''
  source: Nurs Womens Health
  pubdate: 2024 Feb
- pmid: '39241352'
  title: 'Molecular and phenotypic characteristics of respiratory syncytial virus
    isolates recovered from medically vulnerable children: An exploratory analysis
    of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab
    (MEDLEY).'
  authors:
  - name: Tuffy KM
    authtype: Author
    clusterid: ''
  - name: Ahani B
    authtype: Author
    clusterid: ''
  - name: Domachowske JB
    authtype: Author
    clusterid: ''
  - name: Furuno K
    authtype: Author
    clusterid: ''
  - name: Ji H
    authtype: Author
    clusterid: ''
  - name: Madhi SA
    authtype: Author
    clusterid: ''
  - name: Mankad VS
    authtype: Author
    clusterid: ''
  - name: Hamr√©n UW
    authtype: Author
    clusterid: ''
  - name: Villafana T
    authtype: Author
    clusterid: ''
  - name: Wang Y
    authtype: Author
    clusterid: ''
  - name: Kelly EJ
    authtype: Author
    clusterid: ''
  - name: Wilkins D
    authtype: Author
    clusterid: ''
  source: Vaccine
  pubdate: 2024 Oct 24
---

# RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection.

**Authors:** Nodelman, Matthew, Scott, A Miles

**Published in:** American family physician | Vol. 109, No. 6 | 2024-06-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/38905561/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Respiratory Disorders, Family Medicine, Pulmonology

## MeSH Terms

Humans, Respiratory Syncytial Virus Infections, Antiviral Agents, Antibodies, Monoclonal, Humanized, Infant, Palivizumab, Viral Vaccines, Respiratory Syncytial Virus Vaccines

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/38905561/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
